WallStreetZenWallStreetZen

NASDAQ: OKYO
Okyo Pharma Ltd Stock

$1.55-0.44 (-22.11%)
Updated Mar 17, 2023
OKYO Price
$1.55
Fair Value Price
N/A
Market Cap
$42.44M
52 Week Low
$1.54
52 Week High
$7.00
P/E
N/A
P/B
-137.06x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$6.70M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-6.13
Operating Cash Flow
-$5M
Beta
0.22
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

OKYO Overview

OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.

Zen Score

Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how OKYO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

OKYO's cash and short-term investments ($633.63k) cannot cover OKYO's cash burn for the next year ($4.86M), once increasing cash burn (N/A) is accounted for
Interest Coverage Financials
OKYO's short-term liabilities ($1.90M) exceed its short-term assets ($1.58M)
Short-term Liabilities Financials
OKYO's short-term assets ($1.58M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
There are 30 more OKYO due diligence checks available for Premium users.

Be the first to know about important OKYO news, forecast changes, insider trades & much more!

OKYO News

Valuation

OKYO price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
-137.06x
Industry
4.75x

OKYO's financial health

Profit margin

Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
OKYO's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$1.6M
Liabilities
$1.9M
Debt to equity
-6.13
OKYO's short-term liabilities ($1.90M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
OKYO's short-term assets ($1.58M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
OKYO's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
OKYO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
N/A
Investing
N/A
Financing
N/A
OKYO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

OKYO vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
OKYO$42.44M-22.11%N/A-137.06x
RFL$42.30M-2.25%-3.48x0.42x
CGTX$42.67M-4.81%0.16x1.09x
AQST$42.13M+2.64%-0.47x-0.39x
ASLN$41.85M-4.76%-0.92x1.90x

Okyo Pharma Stock FAQ

What is Okyo Pharma's quote symbol?

NASDAQ: OKYO) Okyo Pharma trades on the NASDAQ under the ticker symbol OKYO. Okyo Pharma stock quotes can also be displayed as NASDAQ: OKYO.

If you're new to stock investing, here's how to buy Okyo Pharma stock.

What is the 52 week high and low for Okyo Pharma (NASDAQ: OKYO)?

(NASDAQ: OKYO) Okyo Pharma's 52-week high was $7.00, and its 52-week low was $1.54. It is currently -77.86% from its 52-week high and 0.65% from its 52-week low.

How much is Okyo Pharma's stock price per share?

(NASDAQ: OKYO) Okyo Pharma stock price per share is $1.55 today (as of Mar 17, 2023).

What is Okyo Pharma's Market Cap?

(NASDAQ: OKYO) Okyo Pharma's market cap is $42.44M, as of Mar 20, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Okyo Pharma's market cap is calculated by multiplying OKYO's current stock price of $1.55 by OKYO's total outstanding shares of 1,825,566,753.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.